The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

SIMPLE SUMMARY: The proteasome inhibitor bortezomib is currently commonly used for the treatment of multiple myeloma (MM). MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in messenger RNA silencing and post-transcriptional regulation of gene expression. In MM, the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Paweł, Dróżdż, Izabela, Jarych, Dariusz, Mikulski, Damian, Węgłowska, Edyta, Siemieniuk-Ryś, Monika, Misiewicz, Małgorzata, Stawiski, Konrad, Fendler, Wojciech, Szemraj, Janusz, Smolewski, Piotr, Robak, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565855/
https://www.ncbi.nlm.nih.gov/pubmed/32916955
http://dx.doi.org/10.3390/cancers12092569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565855/
https://www.ncbi.nlm.nih.gov/pubmed/32916955
http://dx.doi.org/10.3390/cancers12092569

Ejemplares similares